Dyne Therapeutics (NASDAQ:DYN) Rating Lowered to Underweight at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) was downgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a report issued on Wednesday, MarketBeat Ratings reports. They currently have a $10.00 target price on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 50.76% from the stock’s previous close.

Several other brokerages have also issued reports on DYN. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Royal Bank Of Canada raised their price objective on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, July 30th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, August 17th. TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating on the stock. Finally, Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They set an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $33.33.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $20.31 on Wednesday. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm’s fifty day simple moving average is $24.82 and its two-hundred day simple moving average is $20.49. Dyne Therapeutics has a 12 month low of $11.92 and a 12 month high of $27.31. The stock has a market capitalization of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, analysts predict that Dyne Therapeutics will post -3.47 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company’s stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares in the company, valued at $6,749,732.16. This represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 4,150,974 shares of company stock valued at $99,697,629 in the last 90 days. Corporate insiders own 9.46% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC bought a new position in Dyne Therapeutics in the 2nd quarter worth about $300,000. Nykredit A S purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at about $113,000. California State Teachers Retirement System boosted its position in shares of Dyne Therapeutics by 2,049.2% during the 2nd quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company’s stock valued at $66,666,000 after acquiring an additional 2,861,952 shares during the last quarter. Moore Capital Management LP grew its holdings in shares of Dyne Therapeutics by 288.2% during the second quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock worth $6,792,000 after purchasing an additional 227,029 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new position in shares of Dyne Therapeutics during the second quarter worth about $222,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month results from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The presentations will include updated safety data and comparisons with a matched natural-history cohort, potentially providing evidence of sustained treatment benefit. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, with topline results still expected in the first quarter of 2027. DYNE-101 also holds FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, which could support an expedited regulatory process if the data are favorable. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity was unusually high, with 20,532 calls purchased versus average volume of roughly 464. The surge may indicate speculative positioning ahead of clinical updates, but it does not establish that the company’s fundamentals have improved.
• Negative Sentiment: Investor sentiment weakened after a competing DM1 therapy failed in a Phase 3 study. Although the result does not directly assess DYNE-101, it raised concerns about the DM1 treatment landscape and increased scrutiny of Dyne’s forthcoming data. RTT News report on rival DM1 failure
• Negative Sentiment: CEO John Cox and other insiders reported sales of shares, including transactions around $18.88 and $24.35. The filings state that the sales were used to cover tax withholding obligations on vested equity awards, and each insider retained a substantial position; nevertheless, the cluster of sales may add to cautious sentiment.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.